MedTrace Logo

Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment

NCT03624751 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 107

Last updated 2026-05-01

No results posted yet for this study

Summary

The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.

Conditions

Interventions

RADIATION

radioiodine

Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan.

Sponsors & Collaborators

  • Taichung Veterans General Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-06
Primary Completion
2028-06-30
Completion
2030-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03624751 on ClinicalTrials.gov